CoChat

A novel DYRK1A (Dual specificity tyrosine phosphorylation‐regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro

Coutadeur, Séverine, Benyamine, Hélène, Delalonde, Laurence, de Oliveira, Catherine, Leblond, Bertrand, Foucourt, Alicia, Besson, Thierry, Casagrande, Anne‐Sophie, Taverne, Thierry, Girard, Angélique, Pando, Matthew P., Désiré, Laurent · 2015 · Journal of Neurochemistry
Cited by 117

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The dual‐specificity tyrosine phosphorylation‐regulated kinase 1A (DYRK 1A) gene is located within the Down Syndrome (DS) critical region on chromosome 21 and is implicated in the generation of Tau and amyloid pathologies that are associated with the early onset Alzheimer's Disease (AD) observed in DS. DYRK 1A is also found associated with neurofibrillary tangles in sporadic AD and phosphorylates key AD players (Tau, amyloid precursor, protein, etc). Thus, DYRK 1A may be an important therapeutic target to modify the course of Tau and amyloid beta (Aβ) pathologies. Here, we describe EHT 5372 (methyl 9‐(2,4‐dichlorophenylamino) thiazolo[5,4‐f]quinazoline‐2‐carbimidate), a novel, highly potent (IC50 = 0.22 nM) DYRK 1A inhibitor with a high degree of selectivity over 339 kinases. Models in which inhibition of DYRK 1A by si RNA reduced and DYRK 1A over‐expression induced Tau phosphorylation or Aβ production were used. EHT 5372 inhibits DYRK 1A‐induced Tau phosphorylation at multiple AD‐relevant sites in biochemical and cellular assays. EHT 5372 also normalizes both Aβ‐induced Tau phosphorylation and DYRK 1A‐stimulated Aβ production. DYRK 1A is thus as a key element of Aβ‐mediated Tau hyperphosphorylation, which links Tau and amyloid pathologies. EHT 5372 and other compounds in its class warrant in vivo investigation as a novel, high‐potential therapy for AD and other Tau opathies. image Inhibition of the dual specificity tyrosine‐phosphorylation‐regulated kinase 1A (DYRK1A) is a new high‐potential therapeutic approach for Alzheimer disease. Here we describe EHT 5372, a novel potent and selective DYRK1A inhibitor. EHT 5372 inhibits DYRK1A‐induced Tau phosphorylation, Aβ production and Aβ effects on phospho‐Tau, including Tau aggregation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.13018

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 117

Metadata

Authors
Coutadeur, S., Benyamine, H., Delalonde, L., de Oliveira, C., Leblond, B., Foucourt, A., Besson, T., Casagrande, A., Taverne, T., Girard, A., Pando, M. P., & Désiré, L.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2015-01-26
Volume
133
Issue
3
Pages
440-451
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2051603499
Cited by
117
References
14
FWCI
4.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.